Summary
ATAI Chart
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results
The atai Life Sciences (NASDAQ:ATAI, ETR:9VC) story has become more attractive following the release of robust Phase 2b trial results for BPL-003 in treatment-resistant depression, analysts at Jefferies believe. BPL-003, an intranasal formulation of DMT developed in partnership in Beckley Psytech, demonstrated rapid, robust and durable antidepressant effects with a single dose.
Atai Life Sciences N.V. Dividends
Atai Life Sciences N.V. Earnings
| 18 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Mar 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
| 18 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 12 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Mar 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
Atai Life Sciences N.V. (ATAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Atai Life Sciences N.V. ever had a stock split?
Atai Life Sciences N.V. Profile
| Biotechnology Industry | Healthcare Sector | Srinivas G. Rao CEO | NASDAQ (NMS) Exchange | N0731H103 Cusip |
| DE Country | 54 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Atai Life Sciences N.V. is a pioneering clinical-stage biopharmaceutical company aimed at revolutionizing the treatment of mental health disorders including depression, anxiety, addiction, and more. Established in 2018, with its roots in Berlin, Germany, and with additional offices in New York and London, Atai Life Sciences is pushing the boundaries of traditional mental health treatment modalities by investing in and developing a wide array of therapeutics. Their mission extends towards addressing the unmet needs in mental health care through a strongly differentiated and diversified portfolio of treatments, embarking on a journey to mitigate the global mental health crisis.
Products and Services
- COMP360 (Psilocybin)
- BPL-003 (Intranasal Formulation)
- TRD
- VLS-01
- ELE-101
- IBX-210
- DMX-1002
- EMP-01
- EGX-A and EGX-B
- RL-007
- GRX-917
- PCN-101 (R-Ketamine)
- KUR-101 (Deuterated Mitragynine)
- RLS-01
A proprietary formulation of psilocybin, currently in a Phase 3 clinical program, focusing on its potential therapeutic effects for mental health disorders.
An innovative intranasal formulation of betahistine in active Phase 2a and 2b clinical studies aimed at treating vertigo with lesser side effects and improved patient outcomes.
A therapeutic under development, details unspecified, targeting treatment-resistant depression.
A transmucosal film in Phase 1b clinical studies targeted at delivering therapeutic agents effectively for mental health conditions.
A serotonergic psychedelic in Phase 1/2a study aimed at treating treatment-resistant depression, showcasing the potential of psychedelics in mental health therapy.
An intravenous formulation of ibogaine under development for treating opioid use disorder, addressing the critical need for effective addiction therapies.
An oral formulation of ibogaine indicated for the treatment of opioid use disorder, exploring a different administration route for ibogaine's therapeutic effects.
An oral formulation of an R-MDMA derivative being developed for post-traumatic stress disorder, expanding the therapeutic options for PTSD.
Psychotropic substances with novel, non-tryptamine structures offering differentiated 5-HT receptor pharmacology, aiming at unique mental health treatment pathways.
An orally bioavailable compound acting as a pro-cognitive neuromodulator, under investigation for the cognitive impairment associated with schizophrenia.
A deuterated version of etifoxine designed for the treatment of generalized anxiety disorder, highlighting an approach to minimize anxiety with potentially reduced side effects.
A subcutaneous formulation of R-ketamine focused on psychiatric indications initially targeting treatment-resistant depression, demonstrating the therapeutic versatility of ketamine.
A formulation of deuterated mitragynine under development for the treatment of opioid use disorder, reflecting on the need for innovative addiction treatments.
Indicated for treatment-resistant depression, RLS-01 represents Atai's dedication to finding solutions for those who haven't responded to existing treatments.
Contact Information
